Comparative Pharmacology
Head-to-head clinical analysis: GANCICLOVIR versus VITRASERT.
Peer-Reviewed Evidence
Head-to-head clinical analysis: GANCICLOVIR versus VITRASERT.
GANCICLOVIR vs VITRASERT
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Ganciclovir is a synthetic guanine nucleoside analog that inhibits viral DNA synthesis by competitively inhibiting viral DNA polymerase and by incorporating into viral DNA, causing chain termination. It requires initial phosphorylation by viral thymidine kinase (CMV) or protein kinase (HSV).
Vitrasert (ganciclovir implant) releases ganciclovir, a nucleoside analog that inhibits cytomegalovirus (CMV) replication by competitively inhibiting viral DNA polymerase (UL54) after intracellular phosphorylation to ganciclovir triphosphate. This results in chain termination and viral DNA synthesis inhibition.
Induction: 5 mg/kg IV every 12 hours for 14-21 days. Maintenance: 5 mg/kg IV every 24 hours. Oral: 1000 mg three times daily with food.
Intravitreal implant containing 0.59 mg fluocinolone acetonide; inserted into the vitreous cavity; releases drug over approximately 36 months; no systemic dosing.
None Documented
None Documented
Clinical Note
moderateGanciclovir + Probenecid
"The serum concentration of Probenecid can be increased when it is combined with Ganciclovir."
Clinical Note
moderateValganciclovir + Probenecid
"The serum concentration of Probenecid can be increased when it is combined with Valganciclovir."
Clinical Note
moderateGanciclovir + Mycophenolic acid
"The serum concentration of Mycophenolic acid can be increased when it is combined with Ganciclovir."
Clinical Note
moderateValganciclovir + Mycophenolic acid
Terminal half-life: 2.5-5.0 hours in normal renal function; prolonged to 10-30 hours in renal impairment; requires dose adjustment for CrCl <70 mL/min
Terminal half-life of 2.8 hours following intravitreal injection; sustained local levels for 2-3 weeks.
Renal excretion: >90% unchanged; biliary/fecal: minimal (<5%)
Primarily biliary/fecal (approximately 90%) with minimal renal excretion (<10% unchanged in urine).
Category D/X
Category C
Antiviral
Antiviral
"The serum concentration of Mycophenolic acid can be increased when it is combined with Valganciclovir."